Sun Eclipsed By Fears Of U.S. FDA Probe At Halol Site
This article was originally published in PharmAsia News
Sun Pharma is under the spotlight. At least five U.S. FDA inspectors, an unusually high number, are learned to be in the middle of a thorough probe at the company’s Halol-based manufacturing site. Fear of a possible negative implication has moved the stock price southward.